Key career officials with the US Food and Drug Administration (FDA) objected to a policy change by the agency to advocate that its approval of a drug preempts patients from suing in state tort liability cases when the patients believe the drug harmed them, according to a report released on October 30 by Rep Henry Waxman (D, Calif) chairman of the House Committee on Oversight and Government Reform (http://oversight.house.gov/documents/20081029102934.pdf).
Mitka M. FDA Preemption. JAMA. 2008;300(22):2599. doi:10.1001/jama.2008.751
Customize your JAMA Network experience by selecting one or more topics from the list below.